Form 4 Filing for BridgeBio Oncology Therapeutics, Inc.

This filing details a stock option grant to Peter F. Lebowitz, a director at BridgeBio Oncology Therapeutics, Inc. The option, for 7,289 shares of Common Stock, was granted on June 16, 2026, with an exercise price of $7.73 per share and an expiration date of June 15, 2036. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, provided Lebowitz continues his service. The filing also includes a Limited Power of Attorney, appointing specific individuals to execute SEC filings on behalf of Lebowitz.